Sophia Schwab

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

Maximilian J. Hochmair, Anna Buder, Sophia Schwab et al. · Targeted Oncology · 2018 · 105 citations · Full text

Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC

Anna Buder, Maximilian J. Hochmair, Sophia Schwab et al. · Journal of Thoracic Oncology · 2018 · 64 citations · Full text

Advanced Egfr-mutated Nsclc, Medicine, Pathology +5

Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non–Small Cell Lung Cancer

Lucian Beer, Maximilian J. Hochmair, Alexander Haug et al. · Clinical Nuclear Medicine · 2019 · 60 citations

Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy

Maximilian J. Hochmair, Sophia Schwab, Otto C. Burghuber et al. · Lung Cancer · 2017 · 55 citations

Cancer Immunosurveillance, Advanced Lung Disease, Significant Treatment Response +11

EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR

Anna Buder, Ulrike Setinek, Maximilian J. Hochmair et al. · Targeted Oncology · 2019 · 42 citations · Full text